關於Akron Biotech |的cGMP細胞因子產品組合

關於Akron Biotech |的cGMP細胞因子產品組合

2021.03.06

本文轉載自原廠電子報:Akron Biotech | www.akronbiotech.com

 

 

Our cGMP Cytokine Portfolio

 

We hope your year is off to a good start. At Akron Biotech, we’ve been busy—manufacturing cGMP ancillary materials, growing our team, developing our product lines, and collaborating on exciting developments in regenerative medicine. We have a number of upcoming events, and we can’t wait to connect with you.

Read on.

 

 

Spotlight: cGMP Recombinant Cytokines and Growth Factors

 

The quality of cytokines and growth factors is critical to a cell or gene therapy’s ultimate success. At Akron, we take an orthogonal approach to protein purification, which ultimately produces clean, high-quality proteins.

 

Our cGMP cytokines feature:  

·     Batch-to-batch consistency

·    ISO-Certified cGMP production with quality-controlled materials

·    eCTD DMFs (Drug Master Files)

·    Lyophilized vials or liquid formulation in syringes

·    Available at commercial scale



Take a look at our cGMP recombinant cytokine and growth factor portfolio.

 

 

The Akron Biotech Blog 

In the rapidly developing industry of advanced therapies, the quality and consistency of ancillary materials take center stage when considering the drug manufacturer’s cost control and the ultimate quality of the end therapy.

 

It is our responsibility as ancillary suppliers to take the initial steps in reducing the inherent variability within our industry. Find out some of the ways Akron measures variation in cytokines.

 

 

Upcoming Events 

 

March 3 @ 8pm ET

 

USP-APEC Center of Excellence for Advanced Therapies Pilot Virtual Workshop

Dr. Claudia Zylberberg, Chief Executive Officer, will speak at this USP-APEC Workshop on raw materials for advanced therapies, in a talk titled, “Selection and sourcing of materials.”

 

Details

March 11 @ 1pm ET 

 

XTalks Webinar: De-risking the Manufacturing of Cell Therapies through Virus-Inactivated Products

Akron Biotech Vice President of Global Sales Robert Margolin, SCB President and ARMI Chief Regulatory Officer Richard McFarland, and Adaptimmune Associate Director of Process Sciences Raymond Luke will discuss strategies for how to ensure the integrity of ancillary materials in the manufacture of advanced therapy products.

 

Details

 

March 23-25

 

Innate Killer Summit

2020 has been a game-changing year for the NK cell community. Join us at the 2021 Innate Killer Summit to discuss the latest findings and approaches.

 

Details

April 6-9

 

ARM | Cell and Gene Meeting on the Med

Connect with our sales team at the virtual Meeting on the Med. Also,  David Smith, President and Chief Commercial Officer, will discuss Akron Biotech’s mission, company history, latest developments.

 

Details

back-Top
open-line

LINE 線上諮詢

亞旭-LINE-QRcode

掃瞄或手機直接點擊條碼

error: Content is protected !!